The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

The retained functionality of the sodium iodide symporter (NIS) expressed in differentiated
thyroid cancer (DTC) cells allows the further utilization of post-surgical radioactive iodine …

The management of radioiodine refractory thyroid cancers (RAIR TC) is challenging for the
clinician. Tyrosine kinase inhibitors classically prescribed in this setting can fail due to …

Recurrent, metastatic disease represents the most frequent cause of death for patients with
thyroid cancer, and radioactive iodine (RAI) remains a mainstay of therapy for these patients …

Approximately 30% of patients with advanced, metastatic differentiated thyroid cancer have
radioiodine-refractory disease, based on decreased expression of the sodium iodide …

Radioiodine-concentrating activity in thyroid tissues has allowed the use of radioiodine as a
diagnostic and therapeutic agent for patients with thyroid disorders such as well …

Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …

Active iodide (I−) transport in both the thyroid and some extrathyroidal tissues is mediated by
the Na+/I− symporter (NIS). In the thyroid, NIS-mediated I− uptake plays a pivotal role in …

The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates
active iodide transport into the thyroid gland and into several extrathyroidal tissues. NIS …

Decreased iodide uptake in de-differentiated thyroid carcinomas impedes radioiodide
therapy. RT-PCR analysis revealed reduced expression of Na+/I− symporter (NIS) mRNA in …